Ketamine Showed Antidepressive Effects in Bipolar Depression Trial

Adjunctive ketamine demonstrated significant antidepressant effects in a small randomized trial involving 63 adult outpatients diagnosed with treatment-resistant bipolar I or II depression. The study, published in the Journal of Clinical Psychiatry, aimed to evaluate the efficacy of ketamine as an add-on therapy for individuals whose depression had not responded to conventional treatments. Participants were randomly assigned to receive either intravenous ketamine infusions or a placebo over a two-week period.

The primary outcome measure was the change in the Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to day 14. Results indicated that patients who received ketamine experienced a statistically significant reduction in depressive symptoms compared to the placebo group. Specifically, the ketamine group showed a mean decrease of 15.2 points on the MADRS scale, while the placebo group saw a decrease of 7.8 points. This difference was highly significant (P < 0.001), suggesting a robust antidepressant effect.

Secondary outcomes included improvements in anxiety symptoms, assessed by the Hamilton Anxiety Rating Scale (HAM-A), and quality of life measures. The ketamine group also reported greater improvements in anxiety and overall well-being. The study noted that the antidepressant effects of ketamine appeared relatively rapidly, with significant differences emerging as early as day 3 post-infusion and sustained through day 14. This rapid onset of action is a key characteristic that distinguishes ketamine from traditional antidepressants, which often take weeks to show efficacy.

Adverse events were generally mild and transient, consistent with previous research on ketamine. The most commonly reported side effects included dizziness, nausea, and headache. No serious adverse events were attributed to ketamine. The researchers concluded that intravenous ketamine is a promising adjunctive treatment for refractory bipolar depression, offering rapid and sustained relief from depressive symptoms. However, they emphasized the need for larger, longer-term studies to further establish its safety and efficacy profile, as well as to determine optimal dosing and administration protocols for this patient population. The trial was conducted by researchers from the Department of Psychiatry at the University of California, San Diego, and was funded by a grant from the National Institute of Mental Health.